The cancer immunotherapy developer, which counts Novo and Lundbeck as investors, filed to raise up to $100m in its initial public offering.
IO Biotech, a Denmark-based cancer therapy developer backed by pharmaceutical companies Novo and Lundbeck, has filed for an initial public offering on the Nasdaq Global Market.
The company has set a $100m placeholder target for the offering and Morgan Stanley, Jefferies, Cowen and Kempen are the joint bookrunners.
Founded in 2014, IO Biotech is developing immunotherapies for melanoma and other cancers. Its technology platform, T-win, facilitates the activation of T-cells that target specific immune inhibitory molecules.
The company’s lead…
